MDT

86.08

+0.56%↑

121.65

+2.99%↑

VEEV

167.9

+0.35%↑

HQY

85.93

+1.81%↑

NEOG

9.5

+2.81%↑

MDT

86.08

+0.56%↑

121.65

+2.99%↑

VEEV

167.9

+0.35%↑

HQY

85.93

+1.81%↑

NEOG

9.5

+2.81%↑

MDT

86.08

+0.56%↑

121.65

+2.99%↑

VEEV

167.9

+0.35%↑

HQY

85.93

+1.81%↑

NEOG

9.5

+2.81%↑

MDT

86.08

+0.56%↑

121.65

+2.99%↑

VEEV

167.9

+0.35%↑

HQY

85.93

+1.81%↑

NEOG

9.5

+2.81%↑

MDT

86.08

+0.56%↑

121.65

+2.99%↑

VEEV

167.9

+0.35%↑

HQY

85.93

+1.81%↑

NEOG

9.5

+2.81%↑

Home・Aktien・Actinium Pharmaceuticals Inc

Actinium Pharmaceuticals Inc

Open

1.28 3.23

Buy Sell

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

1.21

Max

1.33

Schlüsselkennzahlen
By Trading Economics
Einkommen	-809K -5.9M
Gewinnspanne	-6,600
Angestellte	25
EBITDA	-1.3M -6.2M

Empfehlungen
By TipRanks
Empfehlungen	Starkes Kaufsignal
12-Monats-Prognose	+380% upside

Dividenden
By Dow Jones
Nächstes Ergebnis	7. Mai 2026

Marktstatistiken
By TradingEconomics
Marktkapitalisierung	3.9M 35M
Vorheriger Eröffnungskurs	-1.95
Vorheriger Schlusskurs	1.28

Actinium Pharmaceuticals Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

16. Apr. 2026, 23:26 UTC

Heiße Aktien

Stocks to Watch: Netflix, Alcoa, Knight-Swift, NiSource

16. Apr. 2026, 20:41 UTC

Wichtige Markttreiber

Netflix Shares Slide After 2Q Outlook Misses Wall Street's Expectations

16. Apr. 2026, 23:49 UTC

Market Talk

Amplitude's Pivot to Oil-Linked Supply Deal Catches Bull's Eye -- Market Talk

16. Apr. 2026, 23:45 UTC

Market Talk

Nikkei May Decline After Hitting Record High -- Market Talk

16. Apr. 2026, 23:33 UTC

Market Talk

Wichtige Nachrichtenereignisse

Gold Edges Higher on Hopes for U.S.-Iran Deal -- Market Talk

16. Apr. 2026, 22:51 UTC

Market Talk

Netflix Sees Signs That Podcasts May Boost Engagement -- Market Talk

16. Apr. 2026, 22:08 UTC

Ergebnisse

Netflix Chair Reed Hastings to Leave Board in June -- 3rd Update

16. Apr. 2026, 22:06 UTC

Ergebnisse

Lundin Mining: Earnings From Discontinued Ops in 1Q Expected to Be Positively Impacted by Unaudited Gain on Disposal of Eagle Mine, Totaling Approximately $4M >LUN.T

16. Apr. 2026, 22:06 UTC

Ergebnisse

Lundin Mining: Pre-Announces Items Impacting 1Q Results

16. Apr. 2026, 22:06 UTC

Ergebnisse

Lundin Mining: Items of Significant Impact in 1Q Expected to Include Unaudited Realized Losses on Derivative Contracts of Approximately $13M, Primarily Related to Gold Collar Contracts >LUN.T

16. Apr. 2026, 22:06 UTC

Ergebnisse

Lundin Mining: Rev in 1Q Expected to Be Positively Impacted by Unaudited Provisional Pricing Adjustments on Prior-Period Concentrate Sales of Approximately $22M on Pre-Tax Basis >LUN.T

16. Apr. 2026, 22:06 UTC

Ergebnisse

Lundin Mining: Adjustments Primarily Include Upward Adjustments in Relation to Prior-Period Metal Sales >LUN.T

16. Apr. 2026, 20:50 UTC

Market Talk

Ergebnisse

Tech, Media & Telecom Roundup: Market Talk

16. Apr. 2026, 20:50 UTC

Market Talk

Financial Services Roundup: Market Talk

16. Apr. 2026, 20:50 UTC

Market Talk

Wichtige Nachrichtenereignisse

Basic Materials Roundup: Market Talk

16. Apr. 2026, 20:50 UTC

Market Talk

Ergebnisse

Health Care Roundup: Market Talk

16. Apr. 2026, 20:49 UTC

Ergebnisse

SpaceX Is Ready to Go Public. The Stock Market Is Its Rocket. -- Barrons.com

16. Apr. 2026, 20:43 UTC

Ergebnisse

Update: Netflix Stock Falls on Weak Guidance. Founder Reed Hastings Is Leaving the Board. -- Barrons.com

16. Apr. 2026, 20:40 UTC

Market Talk

Ergebnisse

Global Equities Roundup: Market Talk

16. Apr. 2026, 20:40 UTC

Market Talk

Ergebnisse

Netflix Says Engagement Quality Hits New High -- Market Talk

16. Apr. 2026, 20:30 UTC

Heiße Aktien

Stocks to Watch: TSMC, Abbott Laboratories, Nvidia, Netflix -- WSJ

16. Apr. 2026, 20:25 UTC

Ergebnisse

Netflix Stock Falls on Weak Guidance. Founder Reed Hastings Is Leaving the Board. -- Barrons.com

16. Apr. 2026, 20:23 UTC

Ergebnisse

These Stocks Are Today's Movers: AMD, Intel, TSMC, Abbott, Hims, Corning, Schwab, Polaris, and More -- Barrons.com

16. Apr. 2026, 20:19 UTC

Ergebnisse

Netflix Guidance Disappoints. The Stock Is Down. -- Barrons.com

16. Apr. 2026, 20:17 UTC

Ergebnisse

Alcoa: Alumina Costs in the Aluminum Segment Are Expected to Be Favorable by Approximately $20M Sequentially >AA

16. Apr. 2026, 20:17 UTC

Ergebnisse

Alcoa: Based on Higher LME and Midwest Premium Pricing and Expected Higher Shipments, Section 232 Tariff Costs on U.S. Imports of Aluminum From Canada Expected to Increase $35M Sequentially >AA

16. Apr. 2026, 20:16 UTC

Ergebnisse

Alcoa: Expects 2026 Total Aluminum Segment Production and Shipments Ranging Between 2.4M and 2.6M Metric Tons, and Between 2.6M and 2.8M Metric Tons, Respectively >AA

16. Apr. 2026, 20:16 UTC

Ergebnisse

Alcoa: Expects 2026 Total Aluminum Segment Production and Shipments to Remain Unchanged From Its Prior Projection >AA

16. Apr. 2026, 20:16 UTC

Ergebnisse

Alcoa: Expects 2026 Total Alumina Segment Production and Shipments Ranging Between 9.7M to 9.9M Metric Tons, and Between 11.8M and 12.0M Metric Tons, Respectively >AA

16. Apr. 2026, 20:16 UTC

Ergebnisse

Alcoa: Expects 2026 Total Alumina Segment Production and Shipments to Remain Unchanged From Prior Projection >AA

Peer-Vergleich

Kursveränderung

Actinium Pharmaceuticals Inc Prognose

Kursziel

By TipRanks

380% Vorteil

12-Monats-Prognose

Durchschnitt 6 USD 380%

Hoch 9 USD

Tief 4 USD

Basierend auf 3 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Actinium Pharmaceuticals Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Starkes Kaufsignal

3 ratings

Buy

Halten

Sell

Basierend auf 3 Analysten, die in den letzten 3 Monaten Aktienbewertungen für Actinium Pharmaceuticals Inc – Dist abgegeben haben.

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

Über Actinium Pharmaceuticals Inc

Actinium Pharmaceuticals, Inc. develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies. Its Iomab-B is an induction and conditioning agent prior to bone marrow transplant in patients with relapsed and refractory acute myeloid leukemia (r/r AML). The company focuses on advancing its development for product candidate Actimab-A, a therapeutic agent that has demonstrated potential activity in r/r AML patients. In addition, it engages with the National Cancer Institute under the cooperative research and development agreement for the development of Actimab-A in AML and other myeloid malignancies. Its Iomab-ACT, a next generation conditioning candidate, is being developed for improving patient access and outcomes for curative cell and gene therapies. Further, the company's research and development activities primarily focus on advancing various preclinical programs for solid tumor indications. The company holds approximately 235 patents and patent applications, including various patents related to the manufacture of the isotope Ac-225 in a cyclotron. The company is based in New York, New York.